Clinical Research has advanced and there are now clinical trials aiming to prevent memory loss before it begins as well as delay the progression.

Clinical Research has advanced and there are now clinical trials aiming to prevent memory loss before it begins as well as delay the progression.


START NOW
Learn about the A4 Study that Brain Matters Research is currently running.

Learn about the A4 Study that Brain Matters Research is currently running.

Get involved now, before Alzheimer's starts.



Learn more about this study.
One of the largest, most respected private clinical research facilities in the country specializing in Alzheimer's Disease diagnosis, treatment and prevention.

One of the largest, most respected private clinical research facilities in the country specializing in Alzheimer's Disease diagnosis, treatment and prevention.


Join our next trial.
Become a part of the Brain Matters family and receive the best disease-modifying medications that are currently being researched.

Become a part of the Brain Matters family and receive the best disease-modifying medications that are currently being researched.

Alzheimer's research


Find the right clinical trial.
Encouragement.  Assistance.  Resources.  Education.
We specialize in Central Nervous System (CNS) trials, with an emphasis on Alzheimer’s Disease, for which we are recognized as one of the leading top-tier sites in North America.

We specialize in Central Nervous System (CNS) trials, with an emphasis on Alzheimer’s Disease, for which we are recognized as one of the leading top-tier sites in North America.


Contact us.
Patients receive initial assessments, memory testing and examination at no cost.

Patients receive initial assessments, memory testing and examination at no cost.

We care about you and your quality of life.



Be a participant.

WHAT WE OFFER

checkmark-fw Know in 90 - Confidential Comprehensive Evaluations, FREE OF CHARGE
checkmark-fw No Insurance Necessary
checkmark-fw Cutting Edge Research Opportunities
checkmark-fw On-Site Informational seminars & Caregiver Support Groups
checkmark-fw Expedited Access to Local Best In-Class Resources
checkmark-fw Refer-A-Friend Program
checkmark-fw Transportation Assistance
checkmark-fw Monthly “Open House Informational Brunch with the Dr.” (RSVP Required) Call us for upcoming dates!


CONTACT US





Full Name (required)

Email (required)

Phone

I am interested in

 Participating in a Research Study

 Learning more about Brain Matters Research

 Caregiver Support

 Brain Matters Research, as I am a Sponsor

How did you hear about us?

Questions / Comments

Please check the following:

puzz2-fw

Ask the Expert – The Problem with Puzzles

By Alzheimer’s Prevention Bulletin Our October expert is Deborah Blacker, MD, ScD, Professor of Psychiatry at Harvard Medical School and Professor and Deputy Chair, Epidemiology at the Harvard T.H. Chan School of Public Health. Dear Dr. Blacker, I understand that memory games and crossword puzzles are supposed to be good for your brain health. But […]

0 comments

puzzles-fw

Engage Your Brain – Help Prevent Dementia – Alzheimer’s Prevention Bulletin

What’s a 10 Letter Word for Maintaining Your Brain? E-n-g-a-g-e-m-e-n-t For Deborah Blacker, MD, ScD, and her colleagues, brain health and dementia prevention is serious business, but they can sum up a portion of their recent research findings with a humorous anecdote. “A colleague of mine who worked on the study shared this, ‘A patient […]

0 comments

pierre

Good News in Alzheimer’s!

Watch the recording as Dr. Pierre N. Tariot, Director of the Banner Alzheimer’s Institute, discusses the latest research into Alzheimer’s treatment and prevention. In this recording, he examines what we know about Alzheimer’s , including the role of genes in its development. He also talks about risk factors for the disease, important new studies currently […]

0 comments

braint3-fw

T3D Boosts Cognition in Half of Alzheimer’s Patients

DRUG TRIAL VIDEO & ARTICLE: See how the investigational new drug, T3D-959, elicited rapid improvement in cognitive tests in 53% of subjects with Alzheimer’s. Look into the exploratory, open label Phase 2a study. In an open-label exploratory study, 36 subjects with mild to moderate disease (MMSE 14-26) were randomized to receive 1 of 4 doses […]

0 comments

vtv-fw

vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease

Phase 2b Trial Showed Positive Results In Slowing Cognitive Decline High Point, North Carolina (September 7, 2016) vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy), vTv’s Phase 3 placebo-controlled trial of azeliragon, an oral antagonist of the Receptor […]

0 comments